Xilio Therapeutics (XLO) EBIT Margin (2024 - 2026)

Xilio Therapeutics has disclosed EBIT Margin across 3 years of filings, most recently posting 111.57% for Q1 2026.

• EBIT Margin for Q1 2026 came in at 111.57%, up 36116.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 78.98% (up 53506.0% YoY), and the FY2025 annual result was 95.92%, up 85903.0% from the prior year.
• EBIT Margin came in at 111.57% for Q1 2026 at Xilio Therapeutics, down from 86.48% in the prior quarter.
• In the past five years, EBIT Margin ranged from a high of 10.12% in Q3 2025 to a low of 790.55% in Q4 2024.
• The 3-year median for EBIT Margin is 325.22% (2025), against an average of 365.67%.
• Across the five-year window, EBIT Margin jumped 70406 bps in 2025 and jumped 36116 bps in 2026, its largest moves.
• Xilio Therapeutics' EBIT Margin stood at 790.55% in 2024, then jumped by 89 bps to 86.48% in 2025, then fell by 29 bps to 111.57% in 2026.
• The last three EBIT Margin figures came in at 111.57% (Q1 2026), 86.48% (Q4 2025), and 10.12% (Q3 2025), per Business Quant data.